local leader

Houston's Johnson Space Center names history-making new director

Vanessa Wyche is the first Black woman to lead a NASA center. Photo courtesy of NASA

NASA's Johnson Space Center in Houston has witnessed a universe of history-making moments. There's now another milestone to add to the list.

On June 30, Vanessa Wyche was named director of Johnson Space Center, becoming the first Black woman to lead a NASA center. Wyche had been acting director since May 3.

"Vanessa is a tenacious leader who has broken down barriers throughout her career," Pam Melroy, deputy administrator of NASA, says in a news release. "Vanessa's more than three decades at NASA and program experience in almost all of the human spaceflight programs at Johnson is an incredible asset to the agency. In the years to come, I'm confident that Houston will continue to lead the way in human spaceflight."

As director of Johnson Space Center, Wyche now leads more than 10,000 NASA employees and contractors.

"As the home to America's astronaut corps, International Space Station mission operations, the Orion and Gateway programs, and a host of future space developments, Johnson is a world leader in human space exploration and is playing a key role in the next giant leaps in American excellence in space," Wyche says. "I look forward to working with everyone as we push forward to the moon and inspire a new generation of explorers to reach for the stars."

Before being named acting director of Johnson Space Center, Wyche had been deputy director since August 2018. Wyche, a 31-year NASA veteran, also has served as assistant director of the center and director of the center's Exploration Integration and Science Directorate, worked in the executive office of the NASA administrator, served as a flight manager for several space shuttle missions, and has led other center-level technical organizations and programs. The South Carolina native holds bachelor's and master's degrees from Clemson University.

Wyche succeeds Mark Geyer as director of Johnson Space Center. Geyer stepped down in May to focus on his cancer treatment. He had led the center since 2018 as its 12th director. In a video released in May, Geyer said he had been coping with an unidentified form of cancer for about 12 months.

Geyer remains with NASA as a senior adviser to the agency's associate administrator.

NASA Administrator Bill Nelson simultaneously announced Wyche's appointment and Janet Petro's appointment as director of Kennedy Space Center in Florida.

"Both Vanessa and Janet are exceptional leaders who will help propel NASA forward as we venture farther out into the cosmos than ever before," Nelson says. "It's an incredible time at NASA, and with Vanessa and Janet leading the Johnson and Kennedy space centers, NASA will embark on a new era of space exploration — starting with the Artemis I launch to the moon later this year."

Nelson, a former U.S. senator from Florida, became NASA administrator in May following his nomination by President Biden. During his congressional tenure, Nelson was one of NASA's staunchest advocates and even flew aboard the Columbia space shuttle. He succeeds acting NASA Administrator Steve Jurczyk. Jurczyk ran the agency after the departure of Bridenstine in January, at the end of the Trump presidency.

In 2019, Texas Comptroller Glenn Hegar reported the nearly 1,700-acre Johnson Space Center generates an economic impact of $4.7 billion in Texas and supports more than 52,000 jobs.

"NASA's history is intertwined with Texas' history, grit, and can-do spirit, and NASA's future in Texas will be crucial in building tomorrow's Texas economy," Hegar said at the time.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted